References
- Lipinski CA Lombardo F Dominy BW Feeney PJ . Experimental and computational approaches to estimate solubility and permeability in drug discovery and developmental settings . Adv. Drug Deliv. Revs.23 ( 1-3 ), 3 – 25 ( 1997 ).
- Banks WA Kastin AJ Akerstrom V Jaspan JB . Radioactively iodinated cyclo(His-Pro) crosses the blood–brain barrier and reverses ethanol-induced narcosis . Am. J. Physiol.264 ( 5 Pt. 1 ), E723 – E729 ( 1993 ).
- Wager TT Chandrasekaran RY Hou X et al. Defining desirable central nervous system durg space through the alignment of molecular properties, in vitro ADME, and safety attributes . ACS Chem. Neurosci.1 ( 6 ), 420 – 434 ( 2010 ).
- Rankovic Z . CNS physicochemical property space shaped by a diverse set of molecules with experimentally determined exposure in hte mouse brain . J. Med. Chem.60 ( 14 ), 5943 – 5954 ( 2017 ).
- van Meer G Simons K . The function of tight junctions in maintaining differences in lipid composition between the apical and the basolateral surface domains of MDCK cells . EMBO J.5 ( 7 ), 1455 – 1464 ( 1986 ).
- Levin VA . Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability . J. Med. Chem.23 ( 6 ), 682 – 684 ( 1980 ).
- Pan W Kastin AJ . Changing the chemokine gradient: CINC1 crosses the blood–brain barrier . J. Neuroimmunol.115 ( 1-2 ), 64 – 70 ( 2001 ).
- McKerrow JH Lipinski CA . The rule of five should not impede anti-parasitic drug development . Int. J. Parasitol. Drugs Drug Resist.7 ( 2 ), 248 – 249 ( 2017 ).
- Banks WA . Enhanced leptin transport across the blood–brain barrier by alpha1-adrenergic agents . Brain Res.899 ( 1-2 ), 209 – 217 ( 2001 ).
- Urayama A Dohgu S Robinson SM Sly WS Grubb JH Banks WA . Alpha adrenergic induction of transport of lysosomal enzyme across the blood–brain barrier . PLoS ONE10 ( 11 ), e0142347 ( 2015 ).
- Kola I Landis J . Can the pharmaceutical industry reduce attrition rates?Nat. Rev. Drug Discov.3 ( 8 ), 711 – 715 ( 2004 ).
- Waring MJ Arrowsmith J Leach AR et al. An analysis of the attrition of drug candidates from four major pharmaceutical companies . Nat. Rev. Drug Discov.14 ( 7 ), 475 – 486 ( 2015 ).
- Becker RE Greig NH . Lost in translation: neuropsychiatric drug development . Sci. Transl. Med.2 ( 61 ), 61rv66 ( 2010 ).
- Becker RE Greig NH Giacobini E . Why do so many drugs for Alzheimer's disease fail in development? Time for new methods and new practices?J. Alzheimer's Dis.15 ( 2 ), 303 – 325 ( 2008 ).
- Becker RE Greig NH . Neuropsychiatric clinical trials: should they accommodate real-world practices or set standards for clinical practices?J. Clin. Biochem Nutr.29 ( 1 ), 56 – 64 ( 2009 ).
- Becker RE Seeman MV Greig NH Lahiri DK . What can triumphs and tribulations from drug research in Alzheimer's disease tell us about the development of pscyhotropic drugs in general?Lancet Psychiatry2 ( 8 ), 756 – 764 ( 2015 ).
- Hughes JD Blagg J Price DA et al. Physicochemical drug properties associated with in vivo toxicological outcomes . Biorg. Med. Chem. Lett.18 ( 8 ), 4872 – 4875 ( 2008 ).
- Leeson PD Springthorpe B . The influence of drug-like concepts on decision-making in medicinal chemistry . Nat. Rev. Drug Discov.6 ( 11 ), 881 – 890 ( 2007 ).